27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator

Area of Science:

• Endocrinology and Metabolism
• Molecular Pharmacology
• Oncology

Background:

• Estrogen receptors (ERs) regulate critical physiological and pathophysiological processes, including reproduction, bone and cardiovascular health, and breast cancer.
• Selective estrogen receptor modulators (SERMs) exhibit tissue- and context-specific responses, exemplified by tamoxifen.
• The cholesterol metabolite 27-hydroxycholesterol (27HC) has emerged as an endogenous SERM.

Purpose of the Study:

• To provide an overview of ER pharmacology.
• To summarize current research implicating 27HC in diverse diseases.
• To highlight clinical data supporting 27HC's role in disease pathogenesis.

Main Methods:

• Literature review of ER pharmacology.
• Synthesis of existing research on 27HC's biological activities.
• Analysis of clinical data related to 27HC and disease.

Main Results:

• 27HC demonstrates SERM-like activities in conditions such as atherosclerosis, osteoporosis, breast and prostate cancers, and neurodegenerative diseases.
• 27HC concentrations correlate with cholesterol levels, suggesting it may mediate some of cholesterol's biological effects.
• Clinical evidence supports 27HC's involvement in the discussed disease states.

Conclusions:

• 27HC is a significant endogenous SERM with broad implications across multiple disease areas.
• Understanding 27HC's role is crucial for developing novel therapeutic strategies targeting estrogen receptor pathways.
• Further research, particularly clinical studies, is warranted to fully elucidate 27HC's impact on human health and disease.